glp1

Saxenda (liraglutide) tracker

Educational reference for Saxenda (liraglutide). Use it inside TrackPep to log doses, side effects, and rotation sites.

Half-life

13 h

Tmax

11 h

Category

glp1

> PLACEHOLDER — pending clinical review by licensed pharmacist. Saxenda is Novo Nordisk's brand of liraglutide for weight management.

Mechanism

Saxenda is a brand name for liraglutide, a GLP-1 receptor agonist, at the dose used for weight management. See the liraglutide entry for the full mechanism.

Research summary

Saxenda is the liraglutide product approved for chronic weight management (SCALE program). See the liraglutide entry for broader context.

Dosing in the literature

Regimens are individualized and set by a prescribing clinician; they are outside the scope of this summary. See the liraglutide entry.

Reported side effects

As a liraglutide product, gastrointestinal effects are most commonly reported; prescribing information includes class warnings. See the liraglutide entry. This is not a complete safety profile.

Stacking notes

See the liraglutide entry. Combination with other agents is a clinical decision.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

  • Saxenda prescribing information / SCALE program · FDA prescribing information (2014)available via DailyMed; see liraglutide entry

References

Track Saxenda (liraglutide) in TrackPep

Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.